surmount-1 tirzepatide non-diabetic weight loss after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial For the first time, tirzepatide

Mar 23, 2026 No

It may be the difference between sustained weight loss over many months and hitting a premature plateau that no dose increase can overcome

Rotate between these areas weekly

While both medications offer effective paths to losing weight, they work differently and come with their own set of pros and cons

These limitations are not incidental

Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Mounjaro), chronic weight management (under the brand name Zepbound), and most recently in 2024, for the treatment of adults with moderate-to-severe obstructive sleep apnea who have obesity or are overweight with at least one weight-related comorbidity